research Abemaciclib-Associated Skin, Hair, and Nail Toxicities: A Case Report
This report details a case of hair, nail, and pigmentary disorders occurring 10 months after starting abemaciclib for metastatic breast cancer, highlighting that cutaneous side effects, although less frequent, can lead to discontinuation in 25% of cases.


